Lai Pamela M, Collaku Agron, Reed Kenneth
1 Clinical Development and Medical Affairs, GlaxoSmithKline Consumer Healthcare, Warren, NJ, USA.
2 Biostatistics Department, GlaxoSmithKline Consumer Healthcare, Warren, NJ, USA.
J Int Med Res. 2017 Apr;45(2):647-661. doi: 10.1177/0300060517700322. Epub 2017 Mar 27.
Purpose This study was performed to evaluate topical 1% diclofenac/3% menthol gel in treating ankle sprain. Design In this randomized, double-blind, placebo-controlled trial, adolescents and adults with acute ankle sprain (N = 385) applied 4 g of gel containing 1% diclofenac/3% menthol (n = 117), 1% diclofenac (n = 112), 3% menthol (n = 77), or placebo (n = 75) four times daily. The primary outcome was the area under the curve of pain intensity (PI) on movement [0 (no pain) to 10 (extreme pain)] from 24 to 72 hours post-application (AUC). Secondary outcomes included pain relief (PR); PI; time to onset of PR, meaningful PR, cooling, and complete recovery; PI difference; sum of PI difference; total PR; reduction in ankle swelling; and the patient's global assessment of response to treatment. Results There were no statistically significant differences in AUC between 1% diclofenac/3% menthol and placebo, diclofenac, or menthol gels and no meaningful advantages of 1% diclofenac/3% menthol for any secondary outcome. There was a higher incidence of skin and application-site events with 1% diclofenac/3% menthol than with placebo or 1% diclofenac. Conclusion No significant improvement was observed with topical 1% diclofenac/3% menthol gel compared with placebo, 1% diclofenac, or 3% menthol gel in treating pain from ankle sprain. ClinicalTrials.Gov Identifier: NCT02100670.
目的 本研究旨在评估局部应用1%双氯芬酸/3%薄荷醇凝胶治疗踝关节扭伤的效果。设计 在这项随机、双盲、安慰剂对照试验中,急性踝关节扭伤的青少年和成年人(N = 385)每天4次涂抹4克含1%双氯芬酸/3%薄荷醇的凝胶(n = 117)、1%双氯芬酸凝胶(n = 112)、3%薄荷醇凝胶(n = 77)或安慰剂(n = 75)。主要结局是用药后24至72小时运动时疼痛强度(PI)[0(无疼痛)至10(剧痛)]的曲线下面积(AUC)。次要结局包括疼痛缓解(PR);PI;PR、有意义的PR、清凉感和完全恢复的起效时间;PI差值;PI差值总和;总PR;踝关节肿胀减轻情况;以及患者对治疗反应的总体评估。结果 1%双氯芬酸/3%薄荷醇凝胶与安慰剂、双氯芬酸凝胶或薄荷醇凝胶之间的AUC无统计学显著差异,且1%双氯芬酸/3%薄荷醇凝胶在任何次要结局方面均无明显优势。1%双氯芬酸/3%薄荷醇凝胶引起的皮肤及用药部位事件发生率高于安慰剂或1%双氯芬酸凝胶。结论 与安慰剂、1%双氯芬酸凝胶或3%薄荷醇凝胶相比,局部应用1%双氯芬酸/3%薄荷醇凝胶治疗踝关节扭伤疼痛未观察到显著改善。ClinicalTrials.Gov标识符:NCT02100670。